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Abstract
Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD)
together, represent the second most common cause of dementia, after
Alzheimer’s disease (AD). The synaptic dysfunctions underlying the cognitive
decline and psychiatric symptoms observed throughout the development of
PDD and DLB are still under investigation. In this study we examined the
expression level of Dynamin1 and phospho-CaMKII, key proteins of
endocytosis and synaptic plasticity respectively, as potential markers of
molecular processes specifically deregulated with DLB and/or PDD. In order to
measure the levels of these proteins, we isolated grey matter from post-mortem
prefrontal cortex area (BA9), anterior cingulated gyrus (BA24) and parietal
cortex (BA40) from DLB and PDD patients in comparison to age-matched
controls and a group of AD cases. Clinical and pathological data available
included the MMSE score, neuropsychiatric history, and semi-quantitative
scores for AD pathology (plaques - tangles) and for α-synuclein (Lewy bodies).
Changes in the expression of the synaptic markers, and correlates with
neuropathological features and cognitive decline were predominantly found in
the prefrontal cortex. On one hand, levels of Dynamin1 were significantly
reduced, and correlated with a higher rate of cognitive decline observed in
cases from three dementia groups. On the other hand, the fraction of
phospho-CaMKII was decreased, and correlated with a high score of plaques
and tangles in BA9. Interestingly, the correlation between the rate of cognitive
decline and the level of Dynamin1 remained when the analysis was restricted to
the PDD and DLB cases, highlighting an association of Dynamin1 with
cognitive decline in people with Lewy Body dementia.
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Introduction
Dementia with Lewy Bodies (DLB) and Parkinson’s disease demen-
tia (PDD) are together the second most common cause of dementia 
after Alzheimer’s disease (AD) and account for 15–25% of demen-
tias1. They are both characterised by progressive cognitive decline, 
visual hallucinations and Parkinsonism2,3. Lewy body dementias 
(including DLB and PDD) are neuropathologically defined by 
insoluble α-synuclein aggregates in neuronal somata, forming 
Lewy bodies and Lewy neurites in neuronal processes2. However, 
it has been widely reported that Alzheimer-type pathology (most 
often amyloid plaques, but also to lesser extent neurofibrillary tan-
gles) often coexists with Lewy body pathology4–6. When compared 
to the large-scale cortical atrophy of AD and the dopaminergic neu-
ronal cell loss of PD, cortical cell loss in DLB and PDD is less 
extensive7, suggesting that alternative mechanisms may be respon-
sible for the symptoms associated with DLB and PDD. In addition 
to Lewy bodies and Lewy neurites, small aggregates of α-synuclein 
have been identified pre-synaptically in DLB and PDD, raising the 
possibility of a deleterious effect on synaptic function8,9. Alongside 
this, interactions between α-synuclein and synaptic vesicle (SV) 
recycling proteins have previously been described10, suggesting that 
SV proteins are affected by the alterations in concentration of pre-
synaptic α-synuclein11. It has also been shown that dysfunctional 
vesicle regulation can lead to dementia-like cognitive deficits12.
In AD there is substantial synaptic loss, which was revealed to pro-
vide a better indicator for cognitive impairment than the classical 
AD morphological changes13. Although there is emerging evidence 
of synaptic pathology in PD14, much less is known regarding the 
molecular basis and clinical consequences of the synaptic pathol-
ogy associated with PD and DLB compared to AD, which may 
provide an opportunity for therapeutic intervention, through resto-
ration of neurotransmitter tone.
Dynamin1 is a ~ 100kDa protein with GTPase activity, that is 
involved in many intracellular trafficking processes including SV 
recycling, neurotransmitter reuptake and receptor internalization15,16. 
A considerable body of evidence supports a key role in synaptic 
transmission. For example, Dynamin1 interacts with other endo-
cytotic proteins including amphiphysin, endophilin and syndapin 
through its C-terminal proline rich domain (PRD), and as a conse-
quence, pharmacological inhibition leads to disturbance of normal 
SV- and endosome formation17. Furthermore, Dynamin1 knockout 
mice demonstrate defects in SV endocytosis during strong, but not 
mild, neuronal activity18. In addition, Dynamin1 may play a key role 
in establishing and maintaining mature neuronal structure19,20. For 
example, dynamin1 is upregulated during new neurite formation21 
and is down-regulated during neurite retraction, and furthermore, 
silencing the initiation codon for dynamin significantly hampers 
the formation of axon-like structures.
Ca2+/calmodulin-dependent protein kinase II-α (CaMKII) is a pro-
tein kinase highly concentrated in the brain and implicated in syn-
aptic plasticity mechanisms22–24. Synaptic activity-triggered Ca2+ 
influx through NMDA receptor channels can activate CaMKII and 
promote its autophosphorylation at Thr286, which results in a 
persistently active form of the kinase25,26. The resulting CaMKII 
activation is likely to occur at both pre-and postsynaptic sites. At the 
presynaptic site, CaMKII-mediated phosphorylation of synapsin1 
promotes its dissociation from synaptic vesicles, causing increased 
neurotransmitter release27. Activation of a calcineurin-dependent 
phosphatase pathway, however, can dephosphorylate CaMKII and 
reduce its activity28. Interestingly, Calcineurin, which is also acti-
vated by calcium, can dephosphorylate Dynamin1 and therefore 
regulates the SV retrieval processes16.
The synaptic dysfunctions underlying the cognitive decline and 
psychiatric symptoms in DLB and PDD are still poorly understood. 
The relative lack of frank neurodegeneration in DLB and PDD com-
bined with the potential importance of synaptic pathology, together 
with the key role Dynamin1 and CaMKII play in synaptic neuro-
transmission led us to propose the hypothesis that dysfunctional 
synaptic plasticity and disrupted vesicle recycling may contribute 
to cognitive decline. We therefore investigated the concentrations 
of these two key proteins in prefrontal cortex, anterior cingulate, 
and parietal cortex regions of DLB and PDD in comparison to con-
trols and AD in relation with cognitive decline as assessed by serial 
measurements of the Mini-Mental State Examination (MMSE) 
together with semi-quantitative assessments of plaques, tangles and 
Lewy bodies within those regions.
Materials and methods
Participants, diagnosis and clinical assessment
Post-mortem brain tissue was obtained from several sources; Uni-
versity Hospital Stavanger (Norway), the MRC London Neurode-
generative Diseases Brain Bank, the Thomas Willis Oxford Brain 
Collection and the Newcastle Brain Tissue Resource. The UK 
brain banks are part of the Brains for Dementia Research Network. 
All participants gave informed consent for their tissue to be used 
in research and the study had ethics approval from the National 
Research Ethics Service (08/H1010/4). Neuropathological assess-
ment was performed according to standardised neuropathological 
scoring/grading systems, including Braak staging, Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) scores, 
Newcastle/McKeith Criteria for Lewy body disease, National Insti-
tute on Aging - Alzheimer’s Association (NIA-AA) guidelines and 
phases of amyloid-β (Aβ) deposition (Aβ-phases)2,29–32. Controls 
were cognitively normal, with only mild age-associated neuro-
pathological changes (e.g., neurofibrillary tangle Braak stage <II) 
and no history of neurological or psychiatric disease.
Patients were followed prospectively with annual assessments 
including standardized instruments of cognitive, motor and neu-
ropsychiatric symptoms. Cognitive impairment data consisted of 
the last Mini-Mental State Examination (MMSE) scores a maxi-
mum of two years prior to death33. Final diagnoses for patients 
are clinico-pathological consensus diagnoses incorporating the 
one-year rule to differentiate DLB and PDD2. Table 1 shows the 
demographic details of the patients and controls. Biochemical 
and histopathological analysis was undertaken on prefrontal cor-
tex (Brodmann area, BA9), anterior cingulate gyrus (BA24) and 
parietal cortex (BA40). BA9 was selected due to its proposed role 
in executive function and cognition34, decline of which is a cardi-
nal symptom of DLB and PDD, BA24 was selected for the early 
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development of pathology encountered in this region in DLB 
and PDD35 whilst BA40 was selected because of its pathological 
predominance in AD as opposed to DLB and PDD36.
Immunohistochemistry
Semi-quantitative assessments of Aβ, tau and α-synuclein pathol-
ogy were conducted blind to clinical diagnosis, by neuropatholo-
gists, using a scale of 0 (none), 1 (sparse), 2 (mild) and 3 (severe/
frequent) to score sections from BA9, BA24 and BA40 according 
to published criteria35,36. For detection of senile Aβ plaques sec-
tions were stained with an anti-Aβ 1E8 (gift from GSK) or 4G8 
antibody (Covance SIG39220 mouse monoclonal) raised to Aβ17-24, 
at 1:1000. Tau immunohistochemistry (AT8 antibody (Innogenetics) 
at 1:200) and silver impregnation (Gallyas or modified Bielschowsky) 
were used to detect neurofibrillary tangles, neuritic plaques, dys-
trophic neurites and neuropil threads. α-Synuclein pathology was 
detected using NCL-SYN antibody (Novacastra Laboratories) at 
1:200.
Preparation of tissue samples for western blotting
Preparation of tissue for western blotting was as previously 
described37. Briefly, 500mg of frozen tissue was taken from each 
brain region. Meninges, white matter, blood vessels and clots were 
dissected from the frozen tissue to leave approximately 200mg of 
grey matter which was homogenised in ice cold buffer containing 
50mM Tris-HCL, 5mM EGTA, 10mM EDTA, ‘complete protease 
inhibitor cocktail tablets’ (Roche, 1 tablet per 50ml of buffer), and 
2μg/ml pepstatin A dissolved in ethanol:DMSO 2:1 (Sigma). Buffer 
was used at a ratio of 2ml to every 100mg of tissue and homog-
enisation performed using an IKA Ultra-Turrax mechanical probe 
(KIA Werke, Germany) until the liquid appeared homogenous.
Protein concentration was established using the Coomassie (Brad-
ford) Protein Assay Kit (Thermo Scientific), briefly 10μl of crude 
homogenate was diluted 1:50 and read in triplicate at 595nm using 
a FlexStation 3 (Molecular Devices). Concentration was calculated 
using a BSA standard curve run at the same time as samples.
Western blotting
Crude brain homogenate was diluted 4:5 with 5× sample buffer 
(Genscript MB01015), boiled for 5 minutes then stored at -20°C. 
Samples were loaded at 20μg/ml total protein on 10% SDS-poly-
acrylamide gel for protein separation, transferred to nitrocellulose 
membrane (Hydrobond-C, Amersham) and probed with either anti-
totalCaMKIIα (Santa Cruz sc-136212, 1:10000) or anti-phospho-
CaMKII (Santa Cruz sc-12886-R, 1:200) and the relevant secondary 
antibody (IRDye from LI-COR, anti-mouse for total CaMKIIα and 
anti-rabbit for phospho-CaMKII). Bands were detected using an 
Odyssey infrared fluorescent scanner, the integral of intensity quan-
tified using Odyssey infrared imaging systems application software 
version 3.0.16 and expressed as ratios to rat cortex in arbitrary units.
ELISA
Using the crude brain homogenates already prepared, tissue debris 
was then removed by centrifugation maintained at 15000× g for 
15min at 4°C. The resultant supernatant was collected and the pro-
tein concentrations were determined using the Coomassie (Bradford) 
Protein Assay Kit as previously described. Dynamin1 concentration 
was measured using a commercial ELISA kit developed by USC-
NLIFE TM (Wuhan China). The microtiter plate was pre-coated 
with biotinylated polyclonal antibody specific to Dynamin1. 100μl 
standards or samples (10 × diluted) were added and incubated for 
two hours at 37°C. 100μl detection reagent A (avidin conjugated 
to Horseradish Peroxidase (HRP)) was added to each micro plate 
well and incubated for 1hr at 37°C. After washing 4 times, 100μl 
of a TMB (3,3’,5,5’ tetramethyl-benzidine) substrate solution was 
added to each well and incubated for 1hr at 37°C. Colour devel-
oped in proportion to the amount of bound analyte. Finally, the 
enzyme-substrate reaction was terminated by adding 1N sulphu-
ric acid. Quantification of Dynamin1 was achieved measuring col-
our changes using a spectrophotometer at a wavelength of 450nm. 
The concentration of Dynamin1 in the samples was determined by 
comparing the optical density (OD) of the samples to the standard 
curve. Within-assay precision for a replicated sample on the same 
plate (%CV of intra-assay variation) for a selected sample was 
< 6%. The inter-assay variability, (for same sample analyzed on 
three different plates) was < 15%.
Statistical analysis
The normality of the data for each protein was determined using 
the Shapiro-Wilk test and normalised where necessary. In each 
case, the protein values were subsequently expressed as residuals 
(unstandardised) created from the multivariable regression analysis, 
to eliminate the confounding effect of the demographic variables 
(gender, post mortem delay (PMD), age at death, length of brain 
storage) on the protein values. Unstandardised residuals were used 
in all subsequent analyses. We tested for differences in protein lev-
els between groups using one-way ANOVA and Bonferroni post-
hoc test or Kruskall-Wallis ANOVA followed by Mann Whitney 
U test as appropriate Intercorrelations of neurochemical variable and 
correlations with demographic and clinical features were examined 
using Pearson product moment (r) or Spearman rank (Rs) correla-
tion as appropriate. Statistical analyses were conducted using SPSS 
version 20.
Results
Demographics of the cohort used are summarised in Table 1. 
AD patients were significantly older at death (one-way ANOVA 
F(3;126)=6.044, p=0.001) than controls (p=0.001) or patients with 
DLB (p=0.008) or PDD (p=0.001). There were no significant dif-
ferences in PMD, tissue pH or gender between diagnostic groups.
Changes in expression of synaptic proteins with diagnosis
The results for protein expression in the prefrontal cortex, anterior 
cingulate and parietal cortex are shown in Figure 1, Figure 2, and 
in Table 2. Dynamin1 protein levels were not significantly differ-
ent between groups (Kruskall-Wallis p=0.682 for BA9; p=0.120 for 
BA24, Figure 1 and dataset 3 for BA40). On the other hand, changes 
were found for the expression of CaMKII and the fraction of acti-
vated form, i.e. phospho-CaMKII (Table 2). Indeed, the phospho-/ 
total CaMKII ratio was significantly lower in the AD group com-
pared to control, PDD and DLB groups in the prefrontal cortex 
(one-way ANOVA F(3,115)=7.129, p<0.001; Figure 2). In the ante-
rior cingulate cortex, this ratio was decreased in all three demen-
tia groups compared to controls (Kruskall-Wallis χ2(3)=14.44, 
p=0.003; Figure 2). In the same brain region, although the level 
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of Dynamin1 was decreased in the AD group, there was no signifi-
cant difference between groups. In the parietal cortex, expression 
of phospho-CaMKII was significantly lower in PDD, DLB and AD 
compared to controls, with a stronger decrease in the AD group 
(Kruskall-Wallis χ2(3)=35.942, p<0.001; Table 2). The level of the 
ratio phospho-/total CaMKII in the DLB group was decreased com-
pared to other groups (one-way ANOVA F(3,114)=3.45, p=0.019; 
Figure 2).
Correlates between expression of synaptic proteins and 
neuropathological features
Figure 3 summarises the relationships found between synaptic 
markers and semi-quantitative scores of AD pathology in BA9 
and BA40. The ratio phospho-/total CaMKII was decreased, with 
a high score of plaques (Kruskall-Wallis χ2(3)=8.549, p=0.036), 
and medium and high scores of tangles (one-way ANOVA 
F(3,111)=5.375, p=0.002) in BA9. On the other hand, phospho-
CaMKII was significantly decreased with high scores of plaques 
and tangles in BA40 (one-way ANOVA F(3,111)=5.227, p=0.002 
for plaques; one-way ANOVA F(3,112)=9.282, p<0.001 for 
Table 1. Summary of subject demographics. Values are mean ± SEM. DLB: Dementia 
with Lewy Body; PDD: Parkinson’s Disease Dementia; AD: Alzheimer’s Disease. PMD: 
post mortem delay. Age at death, PMD and pH are mean values, MMSE is the median 
score prior to death with range in brackets.
Control DLB PDD AD
Number of cases 25 55 34 16
Age of death (years) 79.8 ± 1.5 81.7 ± 0.9 79.9 ± 1.0 88.0 ± 2.0
PMD (hours) 39.1 ± 4.6 41.3 ± 3.8 33.5 ± 2.7 34.9 ± 6.0
Gender M/F (%) 60/40 56/44 53/47 31/69
Brain pH 6.47 ± 0.07 6.37 ± 0.06 6.44 ± 0.06 6.30 ± 0.08
MMSE (last assessment) n/a 13 (0–30) 13 (0–27) 10.5 (0–19)
Figure 1. Concentration of Dynamin1 in BA9 and BA24 tissues by ELISA from subjects with PDD, DLB, AD and controls. (A) BA9, (B) 
BA24, PDD: Parkinson’s Disease Dementia; DLB: Dementia with Lewy Body; AD: Alzheimer’s Disease. Bars represent mean and error bars 
SEM.
tangles). There was no correlation between Dynamin1 concen-
tration and neuropathological scores in BA9 or BA40 (one-way 
ANOVA, p>0.05, see data sets). No significant relationships were 
found between any neurochemical variable and pathological fea-
tures in the anterior cingulate cortex (one-way ANOVA, p>0.05, 
see data sets).
Synaptic markers expression are decreased with cognitive 
decline
A significant association between MMSE decline per year and 
the level of Dynamin1 was observed in BA9, with a decrease in 
Dynamin1 level with the rate of cognitive decline (r=-0.280, 
p=0.019, n=70; Figure 4). This correlation is also significant when 
the analysis was restricted to the PDD and DLB cases (r=-0.327, 
p=0.014, n=56). In the same brain region, the ratio phospho/total-
CaMKII was positively correlated to the MMSE scores before death 
(r=0.256, p=0.024, n=78), highlighting a decrease in the fraction 
of activated CaMKII protein with the cognitive deficit. However, 
when the AD group was excluded from the analysis, there was no 
correlation between phospho-CaMKII and MMSE.
A B
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related to the rate of cognitive decline observed in our cohort of 
people with Lewy body dementia (DLB and PDD) and AD; this 
relationship remained in the cohort of LBD cases only (when the 
AD group was excluded from the analysis). On the other hand, 
altered p(Thr286)CaMKII levels in AD, PDD and DLB parietal 
cortex, and in AD prefrontal cortex, were associated with high 
scores of plaques and tangles.
Previous studies have identified decreased expression of Dynamin1 
in AD cases, showing particularly a degradation of Dynamin1 at 
early phase of AD38–40. A decrease in Dynamin1 expression could 
Data for synaptic proteins expression levels and patholog ical 
scores in prefrontal cortex, anterior cingulate gyrus and parietal 
cortex
3 Data Files
http://dx.doi.org/10.6084/m9.figshare.987087
Discussion
The main findings of this study are that the Dynamin1 level in 
prefrontal cortex, while unaltered between diagnostic groups, was 
Figure 2. Fraction of phophoCaMKII levels measured by Western blot in BA9, BA24 and BA40 tissues from subjects with PDD, DLB, 
AD and controls. (A) BA9, (B) BA24 and (C) BA40. Bars represent mean of ratio phospho/totalCaMKII and error bars SEM. ** (p<0.05) and 
** (p<0.01) compared to controls, # (p<0.05), ## (p<0.01) and ### (p<0.001) between dementia groups.
Table 2. Total and phospho-CaMKII levels measured by Western blot in BA9, BA24 and BA40 tissues 
from subjects with PDD, DLB, AD and controls. Values represent the means of relative intensity band 
measurements ± SEM. Number in brackets is the number of cases. * (p<0.05), ** (p<0.01) and *** (p<0.001) 
compared to controls.
BA9 BA24 BA40
proteins TotalCaMKII pCaMKII TotalCaMKII pCaMKII TotalCaMKII pCaMKII
control 1.02 ± 0.07 (24)
3.00 ± 0.25 
(24)
0.63 ± 0.05 
(23)
0.75 ± 0.06 
(23)
0.85 ± 0.01 
(24)
1.86 ± 0.03 
(24)
PDD 0.68 ± 0.05 (32) ***
1.95 ± 0.13 
(32) **
0.77 ± 0.03 
(33) ***
0.73 ± 0.05 
(33)
0.85 ± 0.01 
(29)
1.79 ± 0.01 
(30) **
DLB 0.98 ± 0.03 (50)
2.89 ± 0.13 
(50)
0.90 ± 0.03 
(47)
0.80 ± 0.04 
(48)
0.85 ± 0.01 
(48)
1.76 ± 0.02 
(49) **
AD 0.81 ± 0.05 (16)
1.63 ± 0.27 
(16)
0.84 ± 0.03 
(16)
0.60 ± 0.04 
(16)
0.84 ± 0.01 
(16)
1.63 ± 0.01 
(16)
A
B
C
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create defects in synaptic vesicle recycling, neurotransmitter reup-
take and receptor endocytosis18. This would lead to a diminished 
ability of the neuron to regulate synaptic transmission and may 
prove to be an example of one of the processes that initiate synaptic 
dysfunction in dementia. However, Dynamin1 has not previously 
been implicated in LBD. In our cohort, there was no significant dif-
ference in the level of Dynamin1 between diagnosis groups, neither 
was there a correlation between Dynamin1 and neuropathological 
features. This is particularly surprising for AD pathology, as some 
potential links between Dynamin1 expression and Aβ have been 
reported41,42. However, these differences could relate to the rela-
tively small comparison group used for this study. Nevertheless the 
progressive decrease in Dynamin1 in BA9 with the rate of MMSE 
decline provides new evidence for a role of this protein in cognitive 
dysfunction in DLB and PDD.
Figure 3. Correlates between synaptic markers and AD neuropathological features. (A) ratio phospho/totalCaMKII level with plaques 
scores in BA9, (B) ratio phospho/totalCaMKII with plaques scores in BA9, (C) phosphoCaMKII with plaques scores in BA40 and (D) 
phosphoCaMKII with tangles scores in BA40. Scatter plots represent values and bars the mean for each group. º (p<0.05), ºº (p<0.01) and 
ººº (p<0.001).
Figure 4. Correlates between Dynamin1 level in BA9 and rate of 
cognitive decline. Correlation between values of Dynamin1 level in 
BA9 in dementia cases and the MMSE decline per year.
A
B
C D
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The essential role of CaMKII in long-term synaptic plasticity and 
cognitive function is well documented22–24. Here we confirmed this 
finding with a decreased level of phospho-/total CaMKII, specifi-
cally in prefrontal cortex of the AD group. In addition, the level 
was significantly lower in the prefrontal cortex of dementia patients 
with a high score of plaques. Moreover, a lower expression of 
p(Thr286)CaMKII was observed in parietal cortex of patients with 
a high score of plaques. An interesting finding in another study 
was the co-localization of CaMKII-α with senile plaques (SPs)43. 
With respect to the AD-related neuropathology, in vitro experi-
ments indicated that CaMKII might participate in the tau protein 
phosphorylation44,45. Simonian et al.46 found that the majority of 
tangle-bearing neurons in AD brain expressed CaMKII. We also 
found an association between the level of p(Thr286)CaMKII and 
phosphoTau, with a decrease in p/totalCaMKII in prefrontal cortex 
and phospho-CaMKII in parietal cortex of dementia patients with a 
moderate or severe spread of plaques. However, when the AD group 
is excluded from the analysis, there were no correlations between 
phospho-CaMKII and MMSE or pathological features in any brain 
region. This is a key finding, as it may rule out the potential role of 
this kinase in molecular mechanisms leading to the development of 
cognitive decline in Lewy body dementia. However, it does appear 
to confirm previous reports of impaired phosphorylation CaMKII 
in AD47,48.
Taken together, previous studies and the findings reported here sug-
gest that Ca2+ dysregulation in AD, and LBD within selected brain 
regions, may be sufficient to initiate a deregulation in CaMKII- and 
Dynamin1-dependent molecular pathways, and that this, in turn, 
may contribute to cognitive decline.
Data availability
figshare: Data for synaptic proteins expression levels and patholog-
ical scores in prefrontal cortex, anterior cingulate gyrus and parietal 
cortex, http://dx.doi.org/10.6084/m9.figshare.98708749
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There remains uncertainty regarding the relative contributions of alpha-synuclein, tau and amyloid
pathology to the cognitive impairment in the Lewy body dementias (LBDs) - Parkinson’s disease dementia
(PDD) and Dementia with Lewy bodies (DLB). On the justifiable preposition that whatever the underling
pathology, synaptic dysfunction is a key causative mechanism of cognitive change in PDD and DLB (as it
is in Alzheimer’s disease, AD), the authors in this excellent study on postmortem brain tissue examined
expression levels and ratios of two synaptic proteins, Dynamin1 and CaMKII, in PDD and DLB in
comparison with controls and AD, and correlated them with rate of MMSE decline. The key findings were
firstly, that Dynamin1 levels in prefrontal cortex were correlated with rate of cognitive (MMSE) decline in
all three dementia groups despite mean concentrations being no different from controls, and secondly,
that CaMKII levels in parietal cortex were correlated with degree of plaque and tangle formation. Thus, the
authors reasonably conclude that that (calcium-related) synaptic protein pathways are altered in the LBDs
and likely contribute to cognitive impairment.
 
Specific comments:
The authors chose cortical regions according to known affectation in the three dementias. It might
have been of interest to have included the striatum as well given that striatal amyloid changes have
been reported in the LBDs.
 
The AD group comprised greater than 2:1 females to males, whereas the control and LBD groups
comprised more males than females. Is there (and was there) a gender difference in the levels of
the two synaptic proteins examined? If so, could that have had any influence on the results?
 
There is inconsistency in the concentration units of Dynamin1 in figures 1 and 4 (μgm/g protein and
ng/g protein respectively).
 
Figure 4 depicts the significant relationship between Dynamin1 levels and MMSE progression.
Three patients had a decline of around 15 MMSE points per year, a remarkably rapid progression
and considerably greater than the remainder of the dementia patients. Is there something different
about these patients and does the significant relationship still hold if these three are omitted from
the analysis?
The association of Dynamin1 levels with rate of cognitive decline in the face of normal Dynamin1 levels
seems surprising and a clearer explanation of this apparent ambiguity would be welcome.
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This is well -presented study reporting an association between cognitive change and levels of the
synaptic protein Dynamin1 in post-mortem tissue from the prefrontal cortex of Lewy body dementia
patients. There is ongoing debate in the literature as to the respective roles of alpha synuclein, A-beta
peptide and tau pathologies in the pathogenesis of Lewy body dementia so it is interesting to see a
change of focus to the presumed anatomical basis of breakdown in inter-neuronal communication i.e.
synapse loss or dysfunction.
The title is appropriate, the abstract provides a fair summary of the study and the methodology is
described in sufficient detail. The discussion is well written and the conclusion regarding possible links
between deregulation of synaptic proteins and cognitive decline is compelling. Just a couple of
comments:
In this study DLB and PDD are grouped together under the heading of Lewy body dementias. For
those outside the field it would perhaps be useful to provide more detail on the clinical and 
neuropathological (?) differences between the two conditions.
A simple diagram showing the possible functional inter-relationship between Dynamin1 and
CaMKII might be useful to help justify the choice of these two markers to look at synaptic function.
Minor
In the abstract "cingulated" needs changing to cingulate
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